Clareo Health | Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Patients are randomized to 1 of 2 groups for 48 weeks of open-label treatment. Group 1 receives ddI EC plus d4T plus NFV. Group 2 receives Combivir plus NFV. Antiviral activity is determined by the proportion of patients with HIV RNA levels of less than 400 copies/ml at Week 48.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients may be eligible for this study if they:
Are HIV-positive.
Have a viral load of at least 2,000 copies/ml and a CD4 count of at least 200 cells/mm3.
Are at least 18 years old.
Agree to practice sexual abstinence or to use effective barrier methods of birth control (such as condoms).
You may not be if
Patients will not be eligible for this study if they:
Have had severe diarrhea within 30 days of study entry.
Have a history of pancreatic disease or any other serious condition.
Have hepatitis within 30 days of study entry.
Are diagnosed with an opportunistic (AIDS-related) infection at the time of enrollment.
